Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › crizotinib

crizotinib

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of crizotinib

24 trials tracked of crizotinib: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 970 citations.

24Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 9 Phase 1 8 Other / NA 4
  1. Phase 3 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Completed · 970 cited
  2. Phase 3 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients Completed
  3. Phase 3 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants Completed
  4. Phase 2 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy Completed
  5. Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Completed
  6. Phase 2 Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Completed
Show 18 more trials
  1. Phase 2 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
  2. Phase 2 A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Completed
  3. Phase 2 Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Completed
  4. Phase 2 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Completed
  5. Phase 2 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations Completed
  6. Phase 2 Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Completed
  7. Phase 1 A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers Completed
  8. Phase 1 Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule Completed
  9. Phase 1 Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers Completed
  10. Phase 1 Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Completed
  11. Phase 1 A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors Completed
  12. Phase 1 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
  13. Phase 1 Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers Completed
  14. Phase 1 Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers Completed
  15. N/A Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials Completed
  16. N/A Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. Completed
  17. N/A Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS) Completed
  18. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.